Clinical neuropathology practice news 2-2013: Immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny

Matthias Preusser; Martin van den Bent

doi:10.5414/NP300622

Clinical neuropathology practice news 2-2013: Immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny

Matthias Preusser^*, Martin van den Bent

^*Corresponding author for this work

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

4 Citations (Scopus)

Abstract

Isocitrate dehydrogenase 1(IDH1) gene mutations occur in ~ 60 - 90%of diffuse and anaplastic gliomas and secondaryglioblastomas. IDH status is strongly associatedwith patient survival times and IDHtesting is relevant for clinical patient managementand for stratification in clinical trials.A recent interlaboratory ring trial showsthat immunohistochemistry is a highly reliablemethod to detect the most common IDHmutation (R132H), while IDH gene sequencingis less robust. These results support initialimmunohistochemistry and subsequentgene sequencing in cases with negative orinconclusive immunostaining result as validalgorithm for IDH testing. Furthermore, theyhighlight the need for strict quality control ofDNA-based biomarker analyses on formalinfixedand paraffin-embedded tumor samples.

Original language	English
Pages (from-to)	82-83
Number of pages	2
Journal	Clinical Neuropathology
Volume	32
Issue number	2
DOIs	https://doi.org/10.5414/NP300622
Publication status	Published - Mar 2013

Access to Document

10.5414/NP300622

Cite this

@article{a57c868f3638432e8dd944cf382540b4,

title = "Clinical neuropathology practice news 2-2013: Immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny",

abstract = "Isocitrate dehydrogenase 1(IDH1) gene mutations occur in ~ 60 - 90%of diffuse and anaplastic gliomas and secondaryglioblastomas. IDH status is strongly associatedwith patient survival times and IDHtesting is relevant for clinical patient managementand for stratification in clinical trials.A recent interlaboratory ring trial showsthat immunohistochemistry is a highly reliablemethod to detect the most common IDHmutation (R132H), while IDH gene sequencingis less robust. These results support initialimmunohistochemistry and subsequentgene sequencing in cases with negative orinconclusive immunostaining result as validalgorithm for IDH testing. Furthermore, theyhighlight the need for strict quality control ofDNA-based biomarker analyses on formalinfixedand paraffin-embedded tumor samples.",

author = "Matthias Preusser and {van den Bent}, Martin",

year = "2013",

month = mar,

doi = "10.5414/NP300622",

language = "English",

volume = "32",

pages = "82--83",

journal = "Clinical Neuropathology",

issn = "0722-5091",

publisher = "Dustri-Verlag Dr. Karl Feistle",

number = "2",

}

TY - JOUR

T1 - Clinical neuropathology practice news 2-2013

T2 - Immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny

AU - Preusser, Matthias

AU - van den Bent, Martin

PY - 2013/3

Y1 - 2013/3

N2 - Isocitrate dehydrogenase 1(IDH1) gene mutations occur in ~ 60 - 90%of diffuse and anaplastic gliomas and secondaryglioblastomas. IDH status is strongly associatedwith patient survival times and IDHtesting is relevant for clinical patient managementand for stratification in clinical trials.A recent interlaboratory ring trial showsthat immunohistochemistry is a highly reliablemethod to detect the most common IDHmutation (R132H), while IDH gene sequencingis less robust. These results support initialimmunohistochemistry and subsequentgene sequencing in cases with negative orinconclusive immunostaining result as validalgorithm for IDH testing. Furthermore, theyhighlight the need for strict quality control ofDNA-based biomarker analyses on formalinfixedand paraffin-embedded tumor samples.

AB - Isocitrate dehydrogenase 1(IDH1) gene mutations occur in ~ 60 - 90%of diffuse and anaplastic gliomas and secondaryglioblastomas. IDH status is strongly associatedwith patient survival times and IDHtesting is relevant for clinical patient managementand for stratification in clinical trials.A recent interlaboratory ring trial showsthat immunohistochemistry is a highly reliablemethod to detect the most common IDHmutation (R132H), while IDH gene sequencingis less robust. These results support initialimmunohistochemistry and subsequentgene sequencing in cases with negative orinconclusive immunostaining result as validalgorithm for IDH testing. Furthermore, theyhighlight the need for strict quality control ofDNA-based biomarker analyses on formalinfixedand paraffin-embedded tumor samples.

UR - http://www.scopus.com/inward/record.url?scp=84877794373&partnerID=8YFLogxK

U2 - 10.5414/NP300622

DO - 10.5414/NP300622

M3 - Article

C2 - 23442355

AN - SCOPUS:84877794373

SN - 0722-5091

VL - 32

SP - 82

EP - 83

JO - Clinical Neuropathology

JF - Clinical Neuropathology

IS - 2

ER -

Clinical neuropathology practice news 2-2013: Immunohistochemistry pins IDH in glioma - molecular testing procedures under scrutiny

Abstract

Access to Document

Other files and links

Fingerprint

Cite this